Platform technology
Transforming Tumor Data
Into Personalized Immunotherapy.
An innovative precision immunotherapy platform integrating tumor genomic analysis, AI-assisted neoantigen prediction and synthetic DNA technology.
Phase I
Clinical Trial Approved
8 Weeks
Biopsy to Treatment
3-in-1
Synergistic Formulation
The science
——————————————————
Three immune components acting in synergy
ODI-2001 combines three specific immune players — personalized synthetic DNA, a viral component and an immune checkpoint blocking antibody — formulated to induce and amplify a targeted immune response against what makes each tumor biologically unique.
01
Personalized synthetic DNA vector
A synthetic DNA expression system coding for the patient’s most immunogenic tumor neoantigens, identified through AI-driven genomic analysis.
02
MVA Viral Component
An attenuated virus that safely facilitates DNA expression and powerfully stimulates the innate immune system, amplifying the adaptive immune response.
03
Anti-CTLA4 antibody
An immunomodulating antibody that leverages the earliest steps of immune activation, removing inhibitory signals and sustaining the response.
AI at the core
Artificial intelligence makes true personalization possible.
ODI-2001’s personalized component begins with deep genomic analysis of each patient’s tumor. myNEO® proprietary AI predicts which neoantigens will trigger the strongest immune response — forming the basis of a bespoke synthetic DNA vector, constructed uniquely for every patient.
From biopsy to treatment
8 weeks
MANUFACTURING
The synthetic DNA advantage.
Synthetic DNA meets the demands of personalized medicine — in clinical settings, manufacturing speed, safety and cost of goods — delivering an optimal profile for both patients and commercial scale.
Safety
No bacterial contaminants
Cell-free production eliminates endotoxin risk entirely.
Safety
No antibiotic resistance genes
A cleaner regulatory and safety profile for every batch.
Speed
Fast, streamlined processes
Enabling a quick turnaround from biopsy to clinical preparation.
economics
Low cost of goods
A favorable economic profile supporting scalability across indications.